Am. J. Respir. Crit. Care Med., Volume 161, Number 4, April 2000, 1129-1135

Respiratory Function in Survivors of the United Kingdom Extracorporeal Membrane Oxygenation Trial

CAROLINE BEARDSMORE, ISOBEL DUNDAS, KERRY POOLE, KATIE ENOCK, and JANET STOCKS, on behalf of the Collaborative Extracorporeal Membrane Oxygenation Trial

Department of Child Health, University of Leicester, Leicester; Portex Department of Anaesthesia, Institute of Child Health, London; and National Perinatal Epidemiology Unit, Radcliffe Infirmary, Oxford, United Kingdom

Extracorporeal membrane oxygenation (ECMO) improves survival in mature neonates with reversible lung disease. However, ECMO could result in survival of infants with severe respiratory dysfunction who would otherwise have died. Alternatively, infants receiving ECMO might be spared prolonged ventilation and consequent barotrauma, resulting in improved respiratory function. Our aim was to compare respiratory function at 1 yr of age in infants assigned to receive either ECMO or conventional management (CM). Seventy-eight surviving infants of the United Kingdom (UK) ECMO trial (51 in the ECMO group) were studied at 1 yr of age. Questionnaires provided details of respiratory symptoms, and laboratory measurements of respiratory function were made for respiratory rate, tidal volume, lung volume, airway conductance, specific airway conductance, and maximal expiratory flow at FRC (max _FRC). Data were exchanged on floppy disk for cross-analysis and to ensure that investigators were blinded to the status of the infants. There was a wide spectrum of respiratory function, from normal to markedly abnormal. There were few differences between the groups, but in the CM group lung volume was increased (95% confidence intervals [CIs] of the difference in ECMO versus CM subjects: 67; 4 ml), and inspiratory specific conductance was lower (95% CI: 0.03; 0.98 s¹ · kPa¹). There was a trend toward a lower max_FRC (95% CI: 2; 67 ml/s¹ in the CM group. In addition to providing a survival advantage, ECMO did not worsen lung function in infants assigned to receive it. Indeed, their lung function appeared slightly better than that of infants treated conventionally.

This article has been cited by other articles:

				C. S. Beardsmore, J. Westaway, H. Killer, R. K. Firmin, and H. Pandya How Does the Changing Profile of Infants Who Are Referred for Extracorporeal Membrane Oxygenation Affect Their Overall Respiratory Outcome? Pediatrics, October 1, 2007; 120(4): e762 - e768. [Abstract] [Full Text] [PDF]

				K Khambekar, S Nichani, D K Luyt, G Peek, R K Firmin, D J Field, and H C Pandya Developmental outcome in newborn infants treated for acute respiratory failure with extracorporeal membrane oxygenation: present experience Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2006; 91(1): F21 - F25. [Abstract] [Full Text] [PDF]

				W. Hofhuis, E. C. van der Wiel, E. M. Nieuwhof, W. C. J. Hop, M. J. Affourtit, F. J. Smit, A. A. P. H. Vaessen-Verberne, F. G. A. Versteegh, J. C. de Jongste, P. J. F. M. Merkus, et al. Efficacy of Fluticasone Propionate on Lung Function and Symptoms in Wheezy Infants Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 328 - 333. [Abstract] [Full Text] [PDF]

				R. Hamutcu, T. A. Nield, M. Garg, T. G. Keens, and A. C.G. Platzker Long-Term Pulmonary Sequelae in Children Who Were Treated With Extracorporeal Membrane Oxygenation for Neonatal Respiratory Failure Pediatrics, November 1, 2004; 114(5): 1292 - 1296. [Abstract] [Full Text] [PDF]

				A.-F. Hoo, C. Dezateux, J. P. Hanrahan, T. J. Cole, R. S. Tepper, and J. Stocks Sex-Specific Prediction Equations for VmaxFRC in Infancy . A Multicenter Collaborative Study Am. J. Respir. Crit. Care Med., April 15, 2002; 165(8): 1084 - 1092. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594. [Full Text] [PDF]